Study Shows: Patients Experience Longer Survival in Community Oncology
Posted in In the News
New real-world research from Community Oncology Alliance and Flatiron Health shows that patients treated in community oncology settings achieve better or similar survival outcomes compared to national benchmarks.
Key Study Results:
- Eight months longer median survival for patients treated for metastatic breast cancer (mBC) compared to national benchmarks.
- Two months longer median survival for patients treated for metastatic non-small cell lung cancer (NSCLC) compared to national benchmarks.
- Consistently higher survival rates at one, three, and five years relative to national benchmarks.
Researchers analyzed data from nearly 98,000 patients treated at a community oncology practice within the Flatiron Health Research Network (FHRN). Outcomes were compared to population-based estimates from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database.
For patients with cancer, every additional month matters – and this first-of-its-kind study shows that patients receiving care in community oncology practices experienced longer survival compared to national benchmarks. The findings were released at the 2026 Community Oncology Conference in Orlando.
Read the full COA Quality of Care Study results at:
https://mycoa.communityoncology.org/publications/studies-and-reports/quality-of-care